Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-target Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine Maintenance Therapy Treating Oligometastatic Nasopharyngeal Carcinoma
NCT05290194Phase 2Withdrawn
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Planned start Mar 2022; status: withdrawn.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05290194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290194.